H
Harubumi Kato
Researcher at Tokyo Medical University
Publications - 354
Citations - 12019
Harubumi Kato is an academic researcher from Tokyo Medical University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 57, co-authored 354 publications receiving 11342 citations. Previous affiliations of Harubumi Kato include International University of Health and Welfare.
Papers
More filters
Journal ArticleDOI
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
Harubumi Kato,Yukito Ichinose,Morio Ohta,Enjo Hata,Noriaki Tsubota,Hirohito Tada,Yoh Watanabe,Hiromi Wada,Masahiro Tsuboi,Nobuyuki Hamajima,Mitsuo Ohta +10 more
TL;DR: In this article, a combination of uracil and tegafur (often referred to as UFT) taken orally was shown to prolong survival in non-small-cell lung cancer.
Journal ArticleDOI
Hematoporphyrin Derivative and Laser Photoradiation in the Treatment of Lung Cancer
TL;DR: Photoradiation therapy was performed in 13 lung cancer cases and in one case of severely atypical squamous metaplasia following administration of hematoporphyrin derivative, and complete disappearance of metaplastic atypic was obtained.
Journal ArticleDOI
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Shoji Kudoh,Harubumi Kato,Yutaka Nishiwaki,Masahiro Fukuoka,Nakata K,Yukito Ichinose,Masahiro Tsuboi,Soichiro Yokota,Kazuhiko Nakagawa,Moritaka Suga,Haiyi Jiang,Yohji Itoh,Alison Armour,Claire Watkins,Tim Higenbottam,Fredrik Nyberg +15 more
TL;DR: ILD was relatively common in these Japanese patients with NSCLC during therapy with gefitinib or chemotherapy, being higher in the older, smoking patient with preexisting ILD or poor performance status, mainly in the first 4 weeks.
Journal ArticleDOI
Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study
Tomoyuki Goya,Hisao Asamura,Hirokuni Yoshimura,Harubumi Kato,Kaoru Shimokata,Ryosuke Tsuchiya,Yasunori Sohara,Toshimichi Miya,Etsuo Miyaoka +8 more
TL;DR: Findings indicated that the present stages IB and IIA should be merged into the same stage category and the future revision of the TNM staging system should focus on the subdivision of stages I and II.
Journal ArticleDOI
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
Sarah Burdett,Jean Pierre Pignon,Jayne F. Tierney,Hélène Tribodet,Lesley A. Stewart,Cécile Le Péchoux,Anne Auperin,Thierry Le Chevalier,Richard Stephens,Rodrigo Arriagada,Julian P T Higgins,David H. Johnson,Jan P. van Meerbeeck,Mahesh K. B. Parmar,Robert L Souhami,Bengt Bergman,Jean-Yves Douillard,Ariane Dunant,Chiaki Endo,David J. Girling,Harubumi Kato,Steven M. Keller,Hideki Kimura,Aija Knuuttila,Ken Kodama,Ritsuko Komaki,Mark G. Kris,Thomas E. Lad,Tommaso Claudio Mineo,Steven Piantadosi,Rafael Rosell,Giorgio V. Scagliotti,Lesley Seymour,Frances A. Shepherd,Richard Sylvester,Hirohito Tada,Fumihiro Tanaka,Valter Torri,David A. Waller,Ying Liang +39 more
TL;DR: Results from 47 trial comparisons and 11,107 patients demonstrate the clear benefit of adjuvant chemotherapy for patients with histologically diagnosed early stage NSCLC, irrespective of whether chemotherapy was given in addition to surgery or surgery plus radiotherapy.